In recent years, promising evidence has emerged for new pharmacologic treatments for heart failure with reduced ejection fraction (HFrEF); however, gaps in clinician prescribing for the current guideline-directed therapies still exist. Join cardiology experts Ty Gluckman, MD, and Alison Bailey, MD, as they review the current recommendations for guideline-directed medical therapy in HFrEF, discuss strategies for implementing it, and assess the evidence for new and emerging treatments for HFrEF and recently approved agents, including SGLT2 inhibitors, vericiguat, and omecamtiv mecarbil.
What do primary care providers need to know about diabetes, atrial fibrillation, and heart failure? Dr. Matthew Freeby will address topics related to current type 2 diabetes care, with focus on education, medications and newer technologies. Dr. Karol Watson will discuss treatment and prevention of atrial fibrillation, and Dr. Jon Kobashigawa will discuss common questions about heart failure including risk factors, treatment options, lifestyle changes and prevention.
Refresh your skills in managing common cardiovascular conditions in your primary care patient population during this session. Cardiology specialist Ty Gluckman, MD, will review important updates and considerations for managing your patients with hypertension, hypercholesterolemia and heart failure.
Industry Webcast Sponsored by Novartis Pharmaceuticals Corporation; Not for CME/CE Credit
This program will review recent developments in the treatment of patients with chronic heart failure and discuss the important role of the primary care physician.